Compare Quest Diagnostics Inc (DGX) vs iShares MSCI China ETF (MCHI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs iShares MSCI China ETF — how do they compare? Quest Diagnostics Inc trades at $238.39 (market cap $26.21B), while iShares MSCI China ETF trades at $55.01. The key difference: Quest Diagnostics Inc pays a 1.45% dividend while iShares MSCI China ETF pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, iShares MSCI China ETF nearer its low. Which is the better fit depends on your goals.
| DGX | MCHI | |
|---|---|---|
Market Cap | $26.21B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $238.50 | $66.99 |
52-Week Low | $173.49 | $50.48 |
Enterprise Value | $31.97B | — |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
MCHI, the iShares MSCI China ETF, trades at $55.2, down 3.04% over the past day. Technical indicators show a bullish overall signal with strong moving average support, while oscillators are neutral. The ETF is positioned near key support at $55. Recent news highlights China's strong export growth, particularly in AI and tech sectors, and institutional interest, though some funds have reduced holdings. A dividend of $0.36 per share is scheduled for payment in June 2026.
The outlook for MCHI is cautiously optimistic, driven by China's robust export performance and tech sector strength, but tempered by geopolitical tensions and regulatory risks. Investment opportunities include exposure to undervalued Chinese equities and AI-driven growth, while risks involve U.S.-China trade friction and potential economic slowdowns. Investors should weigh these factors against the ETF's current technical strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →
